Table 3. Subjective Cognitive Impairment (CFQa total and factor scores) 7–9 years post surgery of women treated for primary breast cancer, presented by menopausal status and standard treatment protocols (A–E) for systemic therapy.

	Premenopausal at time of surgery, mean (s.d.; n=751)
Treatment Protocolb	A (−CT/−ET) Mean (s.d.)	D (CT) Mean (s.d.)	B (CT+ET) Mean (s.d.)	Unadjusted A vs D/A vs B P-value	Fully adjustedc A vs D/A vs B P-value
N (%)	139 (18.5)	104 (13.9)	508 (67.6)
CFQ total score	32.4 (12.8)	34.4 (13.9)	33.0 (13.7)	0.26/0.67	0.32/0.66
Forgetfulness	13.3 (4.9)	14.2 (5.5)	13.6 (5.4)	0.17/0.50	0.19/0.51
Distractibility	10.2 (4.6)	10.6 (4.7)	10.2 (4.5)	0.55/0.95	0.60/0.89
False triggering	8.1 (4.3)	8.7 (4.7)	8.3 (4.5)	0.30/0.71	0.44/0.85

	Postmenopausal at time of surgery, mean (s.d.; n=1138)
Treatment Protocolb	A (−CT/−ET) Mean (s.d.)	E (CT) Mean (s.d.)	C (ET) Mean (s.d.)	Unadjusted A vs E/A vs C P-value	Fully adjustedc A vs E/A vs C P-value
N (%)	247 (21.7)	165 (14.5)	726 (63.8)
CFQ total score	30.2 (12.0)	30.9 (12.1)	30.1 (11.9)	0.55/0.93	0.75/0.72
Forgetfulness	12.8 (4.6)	12.8 (4.5)	12.9 (4.6)	0.99/0.84	0.91/0.95
Distractibility	9.1 (4.2)	9.1 (4.0)	9.0 (4.0)	0.92/0.85	0.98/0.67
False triggering	7.3 (3.8)	7.6 (3.7)	7.4 (3.9)	0.51/0.86	0.65/0.78

Abbrevaitions: CEF=cyclophosphamide, epirubicin, and fluorouracil; CFQ=Cognitive Failures Questionnaire and subscales; CMF=cyclophosphamide, methotrexate, and fluorouracil; CT=chemotherapy; ET=endocrine treatment.

^aBroadbent et al, 1982; Rast et al, 2009.

^bDanish Breast Cancer Cooperative Group (DBCG) standardized protocols: A=no adjuvant treatment (−CT, −ET); B (CT+ET)=seven cycles of CEF+tamoxifen; C (ET)=tamoxifen+exemestane; D (CT)=seven cycles of CEF; E=CMF.

^cFully adjusted for age, time since treatment, education, marital status, children, mean personal income, mean household income, occupational status, comorbidity, ethnicity, psychiatric history, surgery type, and radiotherapy.